首页> 外文期刊>The Ochsner Journal >Human Subjects Protection in the Era of the Revised Common Rule
【24h】

Human Subjects Protection in the Era of the Revised Common Rule

机译:人类受试者在修订后的共同规则的时代保护

获取原文
           

摘要

The last several years have been a time of significant change for the clinical research enterprise, not only at the national level with the revised regulations, but also at the local level with the growth and transitions in our own health system. As the current and former executive chairs of the Ochsner Institutional Review Board (IRB) system, we thank all of the authors and peer reviewers who made this special issue possible. Because of the revised federal IRB regulations (45 CFR §46, Subpart A) that became effective in January 2019, active review is underway at all US IRBs and human research protection programs about how the new regulations should be understood, implemented, and operationalized. We hope this special edition will assist many as they work through the various issues that have been raised by these changes. Highlights of this special edition issue include the following:White reflects on the fundamental reason we have IRBs and why human subject protection is important.
机译:过去几年是临床研究企业的重大变化的时期,不仅在国家一级与修订后的法规,而且在当地一级以我们自己的卫生系统的增长和过渡。 作为Ochsner机构审查委员会(IRB)制度的当前和前任执行椅,我们感谢所有作者和同行评审员,他们成为可能的问题。 由于2019年1月变得有效的修订的联邦IRB规定(45CFR§46,Subpart A),在所有美国IRB和人类研究保护方案中正在进行积极评审,了解如何理解新的法规,实施和运作。 我们希望这项特别版本可以帮助许多人通过这些变化提出的各种问题。 本特别版问题的亮点包括以下内容:白色反映了我们拥有IRB的根本原因以及为什么人类主体保护很重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号